Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)
This study has been completed.
First Posted: March 27, 2009
Last Update Posted: August 30, 2016
Information provided by (Responsible Party):